Deathwatch: MedMen (MMEN.C) is cutting out everything but the cancer that is killing it

If you've been around this joint for a while, you'll have seen us arguing folks would be silly to invest in MedMen (MMEN.C) if hanging on to your money is a thing you aspire to do. That's not because we have a hate on for the dude-bros running the show, or because they're not a client, or because we're short sellers, or any of the other 50 or so reasons MedMen homers have thrown at us over the last few years as a rationale for us not seeing the company in the same rose-coloured way they do. It's because MedMen is, and has always been, shit.

Colony Capital (CLNY.NYSE) jumps on Brazil growth train with infrastructure acquisition

Whatever your feelings about Brazillian President Jair Bolsonaro, his plan to increase total infrastructure investment through partnerships or privatization seems to be bearing fruit. The Brazil government’s plan to boost the economy through doubling investment in infrastructure to approximately $65 million has drawn some attention from companies sniffing out ways to pad out their bottom line.